Autonomic nervous system as a target for cardiovascular drugs.
1. Drugs acting within the autonomic nervous system (ANS) are of particular interest when autonomic abnormalities are implicated in the development and maintenance of various cardiovascular pathologies. For example, it has been documented that in the early stages of hypertensive disease (i.e. hyperkinetic borderline hypertension) a sympathetic hyperactivity associated with a decreased parasympathetic activity results in increased cardiac output and heart rate. 2. Several classes of drugs acting within the central, as well as the peripheral ANS, are very efficient in treating hypertensive disease. One of these classes of drugs, the second generation of centrally acting drugs, has proved beneficial in this respect because, in addition to their therapeutic efficacy, these drugs are well tolerated. 3. The central nervous system may also be the target for drugs with the potential to treat other cardiovascular diseases. Some recent experimental and clinical data supporting such new perspectives concerning idiopathic dysrhythmias, angina pectoris and congestive heart failure will be summarized.
Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Université Louis Pasteur, CNRS, Faculté de Médecine, Strasbourg, France. Pascal.Bousquet@medecine.u-strasbg.fr
P
P
Bousquet
L
L
Monassier
J
J
Feldman
D000818:Animals; D001341:Autonomic Nervous System / Q000187:drug effects*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D006801:Humans
D002317:Cardiovascular Agents